<DOC>
	<DOC>NCT02054702</DOC>
	<brief_summary>The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia</brief_summary>
	<brief_title>Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following: Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80 Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness Clinical Global Impression Severity of Illness Scale (CGIS) score ≥ 4 (moderately ill) Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator Have been hospitalized &gt; 21 days for the current acute episode at the time of the baseline visit Have a current DSMIVTR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, posttraumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation. Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Psychotic Disorders</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Cognitive testing</keyword>
</DOC>